Neurocrine Biosciences (NBIX) Equity Average (2011 - 2026)

Neurocrine Biosciences has reported Equity Average for 16 years, with the latest figure at $3.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 29.95% year-over-year to $3.3 billion; the trailing twelve-month figure through Mar 2026 stood at $3.3 billion (up 29.95% YoY), and the FY2025 full-year result was $2.9 billion, up 21.18% from the prior year.
• Equity Average for Q1 2026 stood at $3.3 billion, up from $3.1 billion in the prior quarter.
• The five-year high for Equity Average was $3.3 billion in Q1 2026, with the low at $1.4 billion in Q1 2022.
• Historically, Equity Average has averaged $2.2 billion across 5 years, with a median of $2.3 billion in 2024.
• Annual changes were most pronounced in 2024 — Equity Average soared 38.38% — and 2025, when it increased 6.84%.
• Neurocrine Biosciences' Equity Average stood at $1.6 billion in 2022, then jumped by 30.18% to $2.1 billion in 2023, then advanced by 25.38% to $2.7 billion in 2024, then increased by 17.86% to $3.1 billion in 2025, then advanced by 6.45% to $3.3 billion in 2026.
• The last three Equity Average figures came in at $3.3 billion (Q1 2026), $3.1 billion (Q4 2025), and $2.8 billion (Q3 2025), per Business Quant data.